Untitled Document

Mechelen, Belgium; 19 September 2006 - Galapagos NV (Euronext & LSE: GLPG) has placed 1,305,074 new shares in a successful private placement with Fortis Bank NV, at a price of €8.50 per share. Fortis intends to place these new shares with international institutional clients via an accelerated bookbuilding procedure. Galapagos raised gross proceeds of €11.1 million.

The Board of Directors of Galapagos has authorized this capital increase of €11.1 million by the issuance of 1,305,074 new ordinary shares, effective as of 19 September 2006, at a price per share of €8.50, reflecting the average share price on Euronext Amsterdam over the last 30 days. The new shares are expected to be admitted to trading and listing on Eurolist by Euronext Brussels and Euronext Amsterdam and on AiM on 22 September 2006. As a result of the placement, Galapagos will have 14,355,817 ordinary shares outstanding.

"We are very pleased with this capital increase, an expression of confidence in our strategy," said Onno van de Stolpe, Chief Executive Officer of Galapagos. "The proceeds will be instrumental in further developing our programs in bone and joint diseases, with our lead drug in rheumatoid arthritis expected to enter the clinic in 2008."





Home Park News Location The Park The Nucleus Availability Contact User Group	Park News Galapagos raises €11.1 million from new equity issue Mechelen, Belgium; 19 September 2006 - Galapagos NV (Euronext & LSE: GLPG) has placed 1,305,074 new shares in a successful private placement with Fortis Bank NV, at a price of €8.50 per share. Fortis intends to place these new shares with international institutional clients via an accelerated bookbuilding procedure. Galapagos raised gross proceeds of €11.1 million. The Board of Directors of Galapagos has authorized this capital increase of €11.1 million by the issuance of 1,305,074 new ordinary shares, effective as of 19 September 2006, at a price per share of €8.50, reflecting the average share price on Euronext Amsterdam over the last 30 days. The new shares are expected to be admitted to trading and listing on Eurolist by Euronext Brussels and Euronext Amsterdam and on AiM on 22 September 2006. As a result of the placement, Galapagos will have 14,355,817 ordinary shares outstanding. "We are very pleased with this capital increase, an expression of confidence in our strategy," said Onno van de Stolpe, Chief Executive Officer of Galapagos. "The proceeds will be instrumental in further developing our programs in bone and joint diseases, with our lead drug in rheumatoid arthritis expected to enter the clinic in 2008."

	back

Park News